X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (175) 175
Patent (5) 5
Book Chapter (3) 3
Conference Proceeding (2) 2
Publication (2) 2
Book / eBook (1) 1
Book Review (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (94) 94
female (53) 53
male (51) 51
middle aged (45) 45
index medicus (41) 41
melanoma (39) 39
oncology (38) 38
dermatology (36) 36
adult (35) 35
aged (35) 35
melanoma - drug therapy (34) 34
melanoma - pathology (28) 28
cancer (26) 26
skin neoplasms - drug therapy (24) 24
skin neoplasms - pathology (23) 23
malignant-melanoma (19) 19
aged, 80 and over (18) 18
care and treatment (16) 16
melanoma - secondary (15) 15
treatment outcome (15) 15
metastasis (14) 14
metastatic melanoma (13) 13
antineoplastic agents - therapeutic use (12) 12
cell biology (12) 12
further section (12) 12
neoplasm staging (12) 12
tumors (12) 12
medicine, research & experimental (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
biochemistry (10) 10
immunology (10) 10
melanoma - immunology (10) 10
molecular biology (10) 10
animals (9) 9
biochemistry & molecular biology (9) 9
chemotherapy (9) 9
dacarbazine (9) 9
melanoma - diagnosis (9) 9
melanoma - mortality (9) 9
melanoma - therapy (9) 9
mice (9) 9
mutation (9) 9
skin (9) 9
analysis (8) 8
antigen (8) 8
cell line, tumor (8) 8
clinical trials (8) 8
immunotherapy (8) 8
melanoma - metabolism (8) 8
neoplasm metastasis (8) 8
skin cancer (8) 8
skin neoplasms - diagnosis (8) 8
skin neoplasms - mortality (8) 8
survival (8) 8
young adult (8) 8
adolescent (7) 7
cytokines (7) 7
dacarbazine - administration & dosage (7) 7
disease progression (7) 7
expression (7) 7
kaplan-meier estimate (7) 7
melanoma - genetics (7) 7
metastases (7) 7
prognosis (7) 7
proto-oncogene proteins b-raf - genetics (7) 7
skin neoplasms - therapy (7) 7
therapy (7) 7
time factors (7) 7
antineoplastic agents - adverse effects (6) 6
dendritic cells (6) 6
follow-up studies (6) 6
hematology, oncology and palliative medicine (6) 6
identification (6) 6
immunohistochemistry (6) 6
interferon-alpha - administration & dosage (6) 6
medicine & public health (6) 6
rna, messenger - genetics (6) 6
skin neoplasms - immunology (6) 6
antineoplastic agents - administration & dosage (5) 5
basic electric elements (5) 5
carcinoma (5) 5
cells, cultured (5) 5
cutaneous melanoma (5) 5
disease-free survival (5) 5
electric solid state devices not otherwise provided for (5) 5
electricity (5) 5
gene expression (5) 5
gene expression regulation, neoplastic (5) 5
induction (5) 5
interferon-alpha (5) 5
keratinocytes (5) 5
lymphocytes (5) 5
management (5) 5
melanoma - blood (5) 5
melanoma - complications (5) 5
molecular sequence data (5) 5
monoclonal-antibody (5) 5
mutations (5) 5
open-label (5) 5
patients (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1087 - 1095
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e53745
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces... 
REGRESSION | TRIAL | INDUCED SARCOIDOSIS | CTLA-4 BLOCKADE | AUTOIMMUNITY | SAFETY | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY | PATIENT | HYPOPHYSITIS | CANCER | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Liver - drug effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Endocrine System - drug effects | Adult | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Kidney - drug effects | Antineoplastic Agents - immunology | Pancreas - drug effects | Gastrointestinal Tract - drug effects | Melanoma - pathology | CTLA-4 Antigen - immunology | Nervous System - drug effects | Melanoma - drug therapy | Respiratory System - drug effects | Aged | Skin - drug effects | Antimitotic agents | Antigens | Care and treatment | Algorithms | Lymphocytes | Melanoma | Skin | Metastasis | Antineoplastic agents | Skin cancer | Cancer | Aseptic meningitis | Guillain-Barre syndrome | Exanthema | Central nervous system | Blocking antibodies | Cytotoxicity | Oncology | Lymphocytes T | Metastases | CTLA-4 protein | Intestine | Gastroenterology | Meningitis | Internal medicine | Hematology | Sarcoidosis | Dermatology | Management | Regression analysis | Patients | Eosinophilia | Morbidity | Inflammatory bowel disease | Pathology | Side effects | Hospitals | Perforations | Medical prognosis | Antitumor activity | Autoimmune diseases | Endocrinology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 2, pp. 107 - 114
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 616 - 622
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2014, Volume 4, Issue 1, pp. 94 - 109
Journal Article